二重特異性T細胞誘導抗体
https://web.archive.org/web/20110719061528/http://www.micromet.de/fileadmin/template/main/pdf/download/AACR_2008_MCSP_CD33_BiTE_Poster.pdf.
↑ Lutterbuese, R (2008). “Conversion of cetuximab, panitumumab, trastuzumab and omalizumab into T-cell-engaging BiTE antibodies creates novel drug candidates of high potency”. Proc Am Assoc Cancer Res 99: Abs 2402. オリジナルの2011-07-19時点におけるアーカイブ。. https://web.archive.org/web/20110719061543/http://www.micromet.de/fileadmin/template/main/pdf/download/AACR_2008_Herceptin_BiTE_Poster.pdf.
↑ Baeuerle, PA; Reinhardt, C (2009). “Bispecific T-cell engaging antibodies for cancer therapy.”. Cancer Research 69 (12): 4941–4. doi:10.1158/0008-5472.CAN-09-0547. PMID 19509221.